{
    "nct_id": "NCT04569032",
    "official_title": "A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression",
    "inclusion_criteria": "Inclusion Criteria\n\n* Newly diagnosed PTCL, excluding systemic anaplastic large cell lymphoma (sALCL), per the Revised European-American Lymphoma World Health Organization (WHO) 2016 classification\n* The following non-sALCL PTCL subtypes are eligible:\n\n  * PTCL - not otherwise specified (PTCL-NOS)\n  * Angioimmunoblastic T-cell lymphoma (AITL)\n  * Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T cell leukemia virus 1)\n  * Enteropathy-associated T-cell lymphoma (EATL)\n  * Hepatosplenic T-cell lymphoma\n  * Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL)\n  * Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract\n  * Follicular T-cell lymphoma\n  * Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype\n* CD30 expression <10% by local assessment in tumor containing lymph node or other extranodal soft tissue biopsy\n* Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT, as assessed by the site radiologist\n* An Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2\n\nExclusion Criteria\n\n* Current diagnosis of any of the following:\n\n  * sALCL\n  * Primary cutaneous T-cell lymphoproliferative disorders and lymphomas\n  * Mycosis fungoides (MF), including transformed MF\n* History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years. Exceptions are malignancies with a negligible risk of metastasis or death (e.g., 5-year OS â‰¥90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.\n* History of progressive multifocal leukoencephalopathy (PML).\n* Cerebral/meningeal disease related to the underlying malignancy.\n* Prior treatment with brentuximab vedotin or doxorubicin.\n* Baseline peripheral neuropathy Grade 2 or higher (per the NCI CTCAE, Version 4.03) or subjects with the demyelinating form of Charcot-Marie-Tooth syndrome.\n* Left ventricular ejection fraction less than 45% or symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), or myocardial infarction within the past 6 months, or previous treatment with complete cumulative dose of >300 mg/m2 of doxorubicin.\n* Any uncontrolled Grade 3 or higher (per the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}